MU Genomics Core Facility
The primary objective of the Genomics and Bioinformatics Core Facility is to enable the genomic and bioinformatic research goals of the Nutrition and Cancer Center of Biomedical Research Excellence (COBRE). Next Generation Sequencing, microarray-based applications and automated DNA sequencing require sophisticated methods, expensive instrumentation and reagents, and intense data management and analysis. Given that these methods are most efficiently executed in a core facility environment with expertise in biostatistics and bioinformatics, the Genomics and Bioinformatics Core Facility will provide the following services:
(1) microarray-based gene expression profiling and other microarray applications, including bioinformatic and biostatistical support for microarray and other biomedical research analyses,
(2) automated DNA sequencing and genotyping and access to sequence analysis software
(3) access to real-time thermal cyclers for quantitative PCR and to Agilent 2100 Bioanalyzers for DNA/RNA quantitation and quality assessment, and
(4) training in and access to Next Generation Sequencing applications including RNA-Seq, Chip-Seq and microRNA detection. We will acquire an Illumina HiSeq1000 sequencer in April 2011 and expect to begin offering next generation sequencing services in mid 2011.
It is our expectation that the Genomics and Bioinformatics Core Facility will enable COBRE investigators to identify and characterize candidate genes/pathways involved in the mediation of carcinogenesis and tumor progression as influenced by diet. Our services and resulting data will provide direct evidence for testing hypotheses, insights into candidate gene functions, preliminary data for new grant applications. Our centralized expertise will improve time to publication and overall productivity. The Genomics Core has ongoing and planned collaborations with investigators in the Nutrition and Cancer Center. Dr. Elaine Hardman and Philippe Georgel will be using CHIP-On-Chip microarrays to identify changes in chromatin structures in response to omega 3 fatty acids. In this experiment, maternal consumption of omega 3 fatty acids during gestation and lactation of the experimental C(3)1-TAg mice resulted in reduced mammary gland cancer incidence. These investigators hope to identify the epigenetic changes that occurred to reduce risk for cancer and to eventually determine whether this strategy might reduce risk for breast cancer in humans.